Benefits
Abdominal fat and body fat reduction
In a 12-week trial of 95 overweight adults, abdominal fat fell 9.73% on Sinetrol-XPur versus 3.18% on placebo. A 16-week trial of 77 adults found body fat percentage fell about 2 points more than placebo, and a 100-person Korean trial reported more fat mass loss. Most of this research was run by or with the maker.
Reduced waist and hip circumference versus placebo
In the 95-person, 12-week trial, waist circumference fell 5.71% compared with 1.56% on placebo (p<0.0001) and hip circumference fell 4.71% compared with 1.35%. The lead author works for the maker, and the pattern fits modest changes in body shape rather than dramatic weight loss.
Increased fat release in isolated human fat cells (laboratory work)
In isolated human fat cells in the laboratory, Sinetrol inhibited an enzyme called cAMP-phosphodiesterase by 97% and increased fat release about six-fold compared with untreated cells. This is test-tube work, not something measured inside the body, and it is offered as a proposed explanation for the changes seen in the human trial rather than as proof of how it works in people.
Shifted inflammation and oxidative blood markers in one trial
In the 95-person, 12-week trial, C-reactive protein (a marker of inflammation) fell 22.87% while it rose 61% in the placebo group, fibrinogen fell 19.93%, malondialdehyde fell 14.03%, and the antioxidant markers superoxide dismutase and glutathione rose 17.38% and 4.63% (all p<0.01). These are blood markers, not health outcomes, and in the same trial cholesterol and the other lipid measures did not change.
Body weight and BMI
In a 12-week Korean trial (100 enrolled, 86 finished), two 450 mg tablets a day led to significantly more loss of body weight and BMI than placebo (both p=0.002), though body fat percentage did not differ between groups. A small 2008 study of 20 people reported a 5.2 kg weight difference after 12 weeks, a large number from very few people.
Mechanism of action
cAMP-phosphodiesterase inhibition
In laboratory tests on isolated human fat cells, the citrus polyphenols in Sinetrol blocked an enzyme called cAMP-phosphodiesterase. That keeps a cell signal called cAMP high, which switches on the machinery that breaks stored fat down into fatty acids. This has been shown in cells in a dish, not measured directly in people.
Adenosine receptor modulation by caffeine
Caffeine blocks adenosine receptors on fat cells, which normally hold fat breakdown in check. This is a proposed contribution based on how caffeine behaves in general. The trials tested the whole blend, so how much of any effect comes from the caffeine rather than the citrus polyphenols is unknown.
Antioxidant polyphenol activity
Naringin and hesperidin from the citrus extracts, and anthocyanins from the blood orange, neutralise reactive oxygen molecules in laboratory tests, which may be why inflammation and oxidative blood markers shifted in the 12-week trial. Cholesterol and the other lipid measures were unchanged in that trial, so this should not be read as a broader heart or metabolic benefit.
Clinical trials
Randomized, double-blind, placebo-controlled trial of Sinetrol-XPur taken twice daily with meals for 12 weeks, measuring waist and hip circumference, abdominal fat, and inflammation, oxidative stress, lipid, liver and kidney markers. The lead author works for Fytexia, the maker (Dallas et al. 2014, Phytother Res)
95 healthy overweight adults, 47 on Sinetrol-XPur and 48 on placebo; 12 weeks.
Waist circumference fell 5.71% versus 1.56% on placebo (p<0.0001), hip circumference 4.71% versus 1.35%, and abdominal fat 9.73% versus 3.18%. C-reactive protein fell 22.87% while rising 61% on placebo, and fibrinogen, malondialdehyde, superoxide dismutase and glutathione also moved favorably (all p<0.01). The lipid, kidney and liver panels did not change. No adverse effects were reported. The abstract does not give a body weight figure.
Laboratory study of the Sinetrol citrus polyphenol blend on isolated human fat cells, looking at the enzyme cAMP-phosphodiesterase and fat release, plus a small human comparison of 1.4 g a day versus placebo for 12 weeks (Dallas et al. 2008, Phytomedicine)
Isolated human fat cells in the laboratory, plus two groups of 10 overweight volunteers (Sinetrol or placebo).
In the test tube, Sinetrol inhibited cAMP-phosphodiesterase by 97% and increased fat release from isolated human fat cells about six-fold compared with untreated cells. In the small human arm, body fat differed by 15.6% and body weight by 5.2 kg after 12 weeks. With only 10 people per group, those are very large numbers from very few people and should not be taken at face value.
Randomized, double-blind, placebo-controlled trial of two 450 mg Sinetrol-XPur tablets once a day for 12 weeks, run at Korean universities with three co-authors from the Korean company Rpbio (Park et al. 2020, J Med Food)
100 overweight or obese adults enrolled; 86 completed.
Compared with placebo, body weight (p=0.002), BMI (p=0.002) and body fat mass by DEXA (p=0.030) fell more on Sinetrol-XPur. Body fat percentage fell within the Sinetrol group but did not differ from placebo, and abdominal CT and blood measures did not differ between groups. Safety results did not differ between groups.
Randomized, double-blind, placebo-controlled parallel trial of 900 mg a day for 16 weeks with 4 weeks of follow-up, on a normal-calorie diet and usual activity; three authors work for Fytexia (Muralidharan et al. 2026, Int J Food Sci Nutr)
77 overweight or obese but otherwise healthy men and women.
Body fat percentage fell 1.98 points more than placebo after 16 weeks. Lean mass showed a non-significant trend upward (p=0.06) and resting energy expenditure rose within the Sinetrol group. Safety measures stayed normal and no adverse effects were noticed.
Randomized, double-blind, parallel pilot trial of 900 mg a day for 12 weeks; the lead author is from Fytexia, the maker (Cases et al. 2015, Int J Food Sci Nutr)
Overweight men; the abstract does not give the number.
The authors report that body shape slimmed, metabolic markers improved and muscle breakdown was held back, but the abstract gives no figures, so the size of any effect cannot be judged.